TGIF2LX1 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the TGIF2LX1 protein, which is a member of the TGIF (thymine-rich, G-rich, and immunoglobulin-like factors) family. This protein plays a significant role in regulating gene expression and cellular development, particularly in the context of embryonic development and patterning. TGIF2LX1 acts as a transcriptional co-repressor, modulating the activity of various transcription factors by binding to their target genes. Inhibition of TGIF2LX1 is achieved primarily by binding to its critical regions, such as the DNA-binding domain or interaction sites essential for recruiting other proteins involved in transcriptional regulation. By occupying these binding sites, TGIF2LX1 inhibitors effectively disrupt the protein's normal regulatory functions, leading to altered gene expression profiles. Some inhibitors may also function through allosteric mechanisms, binding to regions separate from the active site and inducing conformational changes that diminish the protein's activity. The binding interactions between these inhibitors and TGIF2LX1 are typically stabilized by a range of non-covalent forces, including hydrogen bonds, hydrophobic interactions, van der Waals forces, and ionic interactions.
Structurally, TGIF2LX1 inhibitors demonstrate considerable diversity, enabling specific interactions with different regions of the TGIF2LX1 protein. These inhibitors often incorporate functional groups such as hydroxyl, carboxyl, or amine groups, facilitating strong interactions through hydrogen bonding and ionic interactions with key amino acid residues in the protein's binding pockets. Many TGIF2LX1 inhibitors also feature aromatic rings or heterocyclic structures that enhance hydrophobic interactions with non-polar regions of the protein, thereby contributing to the overall stability of the inhibitor-protein complex. The physicochemical properties of TGIF2LX1 inhibitors, including molecular weight, solubility, lipophilicity, and polarity, are meticulously optimized to ensure effective binding and stability in various biological environments. This balance between hydrophilic and hydrophobic regions allows TGIF2LX1 inhibitors to interact selectively with both polar and non-polar areas of the protein, ensuring robust and efficient inhibition of TGIF2LX1 activity across diverse cellular contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $105.00 $153.00 | 4 | |
As a TGF-β receptor kinase inhibitor, LY364947 could reduce TGIF2LX expression by impeding the activation of its signaling cascade. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $209.00 $352.00 | 3 | |
This selective inhibitor of TGF-β receptor I can potentially suppress TGIF2LX expression by inhibiting TGF-β mediated transcriptional activation. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $75.00 $150.00 $215.00 $650.00 $1224.00 $4296.00 $7818.00 | 8 | |
RepSox is a selective inhibitor of the TGF-β receptor that could diminish TGIF2LX expression by attenuating TGF-β signaling. | ||||||
Pirfenidone | 53179-13-8 | sc-203663 sc-203663A | 10 mg 50 mg | $100.00 $408.00 | 6 | |
This small molecule may indirectly decrease TGIF2LX expression by modulating TGF-β mediated fibrogenic responses. | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | $1740.00 | ||
Halofuginone inhibits TGF-β signaling, possibly leading to reduced TGIF2LX expression by disrupting its downstream gene regulation. | ||||||
Tranilast | 53902-12-8 | sc-200389 sc-200389A sc-200389B sc-200389C | 10 mg 50 mg 1 g 5 g | $30.00 $101.00 $277.00 $959.00 | 2 | |
Tranilast may inhibit TGIF2LX expression by antagonizing TGF-β and reducing its related transcriptional activity. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $86.00 | 3 | |
As a TGF-β receptor I kinase inhibitor, SD-208 could downregulate TGIF2LX expression by blocking the TGF-β signaling pathway. | ||||||
EW-7197 | 1352608-82-2 | sc-507465 | 5 mg | $345.00 | ||
EW-7197 inhibits TGF-β signaling, which could lead to decreased expression of TGIF2LX by interfering with its induction mechanisms. | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | $87.00 $270.00 | 9 | |
This chemical may reduce TGIF2LX expression by inhibiting the kinase activity of TGF-β receptor I, thus blocking its signaling pathway. | ||||||
Ceralasertib | 1352226-88-0 | sc-507439 | 10 mg | $573.00 | ||
Vactosertib, by inhibiting TGF-β receptor I, could potentially decrease TGIF2LX expression through suppression of its signaling pathway. | ||||||